Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5606835 | 0.78 | LMNA (0.41) | MAPK1CYP2D6HTT | |
| SCHEMBL18206866 | 0.76 | EGLN1 (0.37) | CTSKCYP2D6CA1CA2CA7 | |
| SCHEMBL18206869 | 0.76 | EGLN1 (0.37) | CTSKCYP2D6CA1CA2CA7 | |
| SCHEMBL5547017 | 0.75 | DGAT1 (0.36) | MAPK1CTSKCYP2D6CA1CA2 | |
| SCHEMBL10904902 | 0.75 | MAPK1 (0.37) | MAPK1 | |
| SCHEMBL7361092 | 0.74 | TSHR (0.44) | CA1CA2CA7NOS1NOS3 | |
| SCHEMBL7361094 | 0.74 | TSHR (0.44) | CA1CA2CA7NOS1NOS3 | |
| SCHEMBL18206813 | 0.74 | TSHR (0.44) | CA1CA2CA7NOS1NOS3 | |
| SCHEMBL19719243 | 0.74 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL18206584 | 0.74 | SMN1; SMN2 (0.36) | CTSKCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120052041-A1 | POLYMERIC NANOPARTICLES WITH ENHANCED DRUG-LOADING AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052041-A1 | POLYMERIC NANOPARTICLES WITH ENHANCED DRUG-LOADING AND METHODS OF USE THEREOF | LDHB, ADH1A, AKR1B10 | MAPK1 2137/4885CTSK 4343/4885CYP2D6 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.